Mizuho Medy Co.,Ltd. (4595.T)
JPY 1490.0
(0.34%)
JPY 1490.0
(0.34%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8.71 Billion JPY | -0.16% |
| 2022 | -8.7 Billion JPY | -101.13% |
| 2021 | -4.32 Billion JPY | -902.65% |
| 2020 | 539.03 Million JPY | 16.9% |
| 2019 | 461.09 Million JPY | 175.14% |
| 2018 | 167.58 Million JPY | 308.69% |
| 2017 | -80.3 Million JPY | -110.33% |
| 2016 | 777.65 Million JPY | -5.9% |
| 2015 | 826.45 Million JPY | -10.36% |
| 2014 | 921.95 Million JPY | 10.81% |
| 2013 | 832 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -9.54 Billion JPY | -13.89% |
| 2024 Q1 | -9.79 Billion JPY | -12.32% |
| 2023 Q2 | -9.94 Billion JPY | -14.96% |
| 2023 Q3 | -8.92 Billion JPY | 10.21% |
| 2023 FY | -8.71 Billion JPY | -0.16% |
| 2023 Q4 | -8.71 Billion JPY | 2.34% |
| 2023 Q1 | -8.64 Billion JPY | 0.63% |
| 2022 Q3 | -5.97 Billion JPY | -9.41% |
| 2022 Q1 | -3.33 Billion JPY | 22.85% |
| 2022 FY | -8.7 Billion JPY | -101.13% |
| 2022 Q2 | -5.46 Billion JPY | -63.7% |
| 2022 Q4 | -8.7 Billion JPY | -45.55% |
| 2021 Q2 | -596.36 Million JPY | -267.29% |
| 2021 Q4 | -4.32 Billion JPY | -73.05% |
| 2021 FY | -4.32 Billion JPY | -902.65% |
| 2021 Q1 | 356.47 Million JPY | -33.87% |
| 2021 Q3 | -2.5 Billion JPY | -319.23% |
| 2020 Q1 | 119.87 Million JPY | -74.0% |
| 2020 Q3 | 156.83 Million JPY | 222.8% |
| 2020 FY | 539.03 Million JPY | 16.9% |
| 2020 Q4 | 539.03 Million JPY | 243.68% |
| 2020 Q2 | -127.72 Million JPY | -206.55% |
| 2019 Q3 | 252.03 Million JPY | 189.3% |
| 2019 FY | 461.09 Million JPY | 175.14% |
| 2019 Q2 | -282.21 Million JPY | -217.32% |
| 2019 Q1 | 240.55 Million JPY | 43.54% |
| 2019 Q4 | 461.09 Million JPY | 82.95% |
| 2018 Q4 | 167.58 Million JPY | 158.32% |
| 2018 Q2 | -747.8 Million JPY | -713.33% |
| 2018 Q3 | -287.37 Million JPY | 61.57% |
| 2018 Q1 | 121.92 Million JPY | 251.83% |
| 2018 FY | 167.58 Million JPY | 308.69% |
| 2017 FY | -80.3 Million JPY | -110.33% |
| 2017 Q2 | -479.78 Million JPY | -2431.9% |
| 2017 Q3 | -168.98 Million JPY | 64.78% |
| 2017 Q4 | -80.3 Million JPY | 52.48% |
| 2017 Q1 | 20.57 Million JPY | -97.35% |
| 2016 Q1 | 402.53 Million JPY | -51.29% |
| 2016 Q4 | 777.65 Million JPY | 229.16% |
| 2016 Q3 | 236.25 Million JPY | 959.34% |
| 2016 Q2 | 22.3 Million JPY | -94.46% |
| 2016 FY | 777.65 Million JPY | -5.9% |
| 2015 Q4 | 826.45 Million JPY | 0.0% |
| 2015 FY | 826.45 Million JPY | -10.36% |
| 2014 FY | 921.95 Million JPY | 10.81% |
| 2013 FY | 832 Million JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 1.22 Billion JPY | 811.548% |
| Takeda Pharmaceutical Company Limited | 4385.95 Billion JPY | 100.199% |
| Sumitomo Pharma Co., Ltd. | 389.83 Billion JPY | 102.236% |
| Shionogi & Co., Ltd. | -346.47 Billion JPY | 97.484% |
| Wakamoto Pharmaceutical Co.,Ltd. | -3.56 Billion JPY | -144.562% |
| Nippon Shinyaku Co., Ltd. | -42.15 Billion JPY | 79.323% |
| Kaken Pharmaceutical Co., Ltd. | -61.47 Billion JPY | 85.821% |
| Eisai Co., Ltd. | -97.93 Billion JPY | 91.099% |
| Morishita Jintan Co., Ltd. | -667 Million JPY | -1206.816% |
| Hisamitsu Pharmaceutical Co., Inc. | -51.82 Billion JPY | 83.18% |
| Mochida Pharmaceutical Co., Ltd. | -32.92 Billion JPY | 73.523% |
| Fuso Pharmaceutical Industries,Ltd. | 7.6 Billion JPY | 214.66% |
| Nippon Chemiphar Co., Ltd. | 7.78 Billion JPY | 212.022% |
| Tsumura & Co. | 1.61 Billion JPY | 639.719% |
| Kissei Pharmaceutical Co., Ltd. | -44.16 Billion JPY | 80.262% |
| Torii Pharmaceutical Co., Ltd. | -34.43 Billion JPY | 74.689% |
| Towa Pharmaceutical Co., Ltd. | 172.7 Billion JPY | 105.047% |
| Fuji Pharma Co., Ltd. | 26.62 Billion JPY | 132.739% |
| Zeria Pharmaceutical Co., Ltd. | 28.98 Billion JPY | 130.076% |
| KYORIN Holdings, Inc. | 7.06 Billion JPY | 223.463% |
| Taiko Pharmaceutical Co.,Ltd. | 704 Million JPY | 1338.134% |
| Daito Pharmaceutical Co.,Ltd. | 5.99 Billion JPY | 245.468% |
| SymBio Pharmaceuticals Limited | -6.51 Billion JPY | -33.749% |
| MedRx Co., Ltd | -1.72 Billion JPY | -406.771% |
| Solasia Pharma K.K. | -668 Million JPY | -1204.86% |
| Modalis Therapeutics Corporation | -1.47 Billion JPY | -492.579% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | -7.25 Billion JPY | -20.177% |
| Sawai Group Holdings Co., Ltd. | 56.52 Billion JPY | 115.421% |
| Cyfuse Biomedical K.K. | -2.96 Billion JPY | -194.398% |
| Toho Holdings Co., Ltd. | -98.42 Billion JPY | 91.144% |
| Koa Shoji Holdings Co.,Ltd. | -11.12 Billion JPY | 21.682% |